First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
The new site enables end-to-end production of viral vector gene therapies
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Prior to this appointment, he served as Vice-Chancellor of Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur,
Subscribe To Our Newsletter & Stay Updated
